Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
8.86
-0.09 (-1.01%)
Feb 21, 2025, 4:00 PM EST - Market closed
Pharming Group Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Pharming Group stock have an average target of 27, with a low estimate of 14 and a high estimate of 37. The average target predicts an increase of 204.74% from the current stock price of 8.86.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 17, 2024.
Analyst Ratings
The average analyst rating for Pharming Group stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 2 | 2 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +317.61% | Dec 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +317.61% | Dec 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +317.61% | Dec 11, 2024 |
| Jefferies | Jefferies | Strong Buy Initiates $14 | Strong Buy | Initiates | $14 | +58.01% | Dec 9, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $31 → $30 | Buy | Maintains | $31 → $30 | +238.60% | Oct 28, 2024 |
Financial Forecast
Revenue This Year
294.58M
from 245.32M
Increased by 20.08%
Revenue Next Year
321.74M
from 294.58M
Increased by 9.22%
EPS This Year
-0.02
from -0.02
EPS Next Year
-0.01
from -0.02
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 303.9M | 358.5M | 434.0M | |||
| Avg | 294.6M | 321.7M | 353.0M | |||
| Low | 277.3M | 284.3M | 273.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 23.9% | 21.7% | 34.9% | |||
| Avg | 20.1% | 9.2% | 9.7% | |||
| Low | 13.1% | -3.5% | -14.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.01 | 0.04 | 0.11 | |||
| Avg | -0.02 | -0.01 | 0.00 | |||
| Low | -0.02 | -0.06 | -0.06 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.